Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan and Gemcitabine in Recurrent Platinum-Sensitive Ovarian Cancer
NCT00061308Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2002
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of topotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by GSK. Primary endpoint: Response Rate. Started Dec 2002; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00061308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061308.